Phaseline

Companies › Compugen

Compugen: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
COM701
Experimental antibody
–Phase 1Ovarian CancerMar 2027
COM503–Phase 1NeoplasmNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06888921COM701Phase 1Ovarian CancerOncologyMar 2027
NCT06759649COM503Phase 1NeoplasmOncologyNov 2027

From the company's SEC filings

Cash and short-term investments of $100m on 2025-12-31; operating cash flow positive

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.